Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 17, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,350,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,154.5 pence per share; lowest price paid was 1,127.5 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 493,224,284 shares in Treasury (including unsettled purchases), representing 9.52% of total issued share capital.
- Shares in Issue: 5,180,820,675 shares (excluding Treasury shares).
- Voting Rights in Treasury: The Company holds 8.64% of total voting rights in Treasury.
Material Changes
The primary material change is the reduction of outstanding share capital through the purchase and subsequent cancellation of 1,350,000 shares. This transaction increased the proportion of shares held in Treasury to 9.52% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,180,820,675) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on diluted earnings per share calculations.
- Review the remaining authorization for share buybacks under the mandate granted on May 6, 2010.